Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2016 Feb 3;4(3):225–233. doi: 10.1158/2326-6066.CIR-15-0200-T

Figure 4. Evaluating MYPT1 and PSMC5 expression in biliary, lung, liver, colon and breast cancers using tissue microarrays.

Figure 4

(A) Comparing cytoplasmic and membranous MYPT1 staining in PDA (n = 44) versus biliary (n = 90), lung (n = 91), liver (n = 36), colon (n = 72) and breast (n = 54) cancers. Both cytoplasmic as well as membranous expression of MYPT1 is PDA-specific (P < 0.01). (B) Comparing cytoplasmic and nuclear PSMC5 staining in PDA (n = 45) versus biliary (n = 82), lung (n = 83), liver (n = 36), colon (n = 57) and breast cancers (n = 54). Nuclear expression of PSMC5 is PDA-specific (P < 0.01). However, cytoplasmic expression of PSMC5 is significant expressed in PDA compared to 72% lung, 59% liver and 48% colon but not 88% breast cancer.